Peer Review History

Original SubmissionSeptember 18, 2024
Decision Letter - Ari Samaranayaka, Editor

PONE-D-24-41348Health-related quality of life and its predictors among chronic kidney disease patients: A hospital-based cross-sectional studyPLOS ONE

Dear Dr. karim,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Dec 27 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Ari Samaranayaka, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. Thank you for stating in your Funding Statement:

“The project was completed under the research grant scheme for Dhaka University Teacher (2023-24) that is financially supported by the University Grant Commission (UGC), Bangladesh.”

Please provide an amended statement that declares *all* the funding or sources of support (whether external or internal to your organization) received during this study, as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now.  Please also include the statement “There was no additional external funding received for this study.” in your updated Funding Statement.

Please include your amended Funding Statement within your cover letter. We will change the online submission form on your behalf.

3. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

4. We note that your Data Availability Statement is currently as follows: [All relevant data are within the manuscript and its Supporting Information files.]

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories.

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

Additional Editor Comments (if provided):

• Abstract says logistic regression was used in the analysis. But not presented any results from that analysis. Main text says multivariate regression was done, what analyses done here is unclear, please elaborate.

• Noted the conclusions were generalized to Bangladeshi CKD population. However the recruitment of participants was from a single hospital. How representative these participants to the Bangladeshi CKD population?

• Authors presented a formula used to calculate the sample size, need to define each notation in that formula. Appears the sample size was determined to estimate a proportion with a pre-specified precision. But there is no such an estimation in analysis or results sections. Instead, analysis appeared used linear regression, it is also different to the logistic regression mentioned in the abstract. Therefore sample size estimation incompatible with the analysis done.

• Noted the number of participants was same as the estimated sample size. How did you select that number of people from all eligible patients in that hospital in that period?

• Main source of the data was questionnaires (in addition extracting from medical records). What is the mode of interviews (online?, face to face?, assisted? If so by whom?, etc). Measures taken to mitigate possible bias (eg, social desirability bias) introduced by that?

• Main outcome measure is the KDQoL score along with its dimension scores. Could you explain these scores? Eg, what is/are the possible ranges of these scores? Higher scores indicate better or worse HRQoL?

• Statistical method section says SPSS was used for statistical analysis. Then later says Stata was used for multivariable regression. Does that mean multivariable analysis is not a statistical analysis? Throughout the manuscript authors used the terms multivariate and multivariable interchangeably. These two types of analyses are very different, they haven’t done a multivariate analysis.

• Page 14. Typo. “in sufficient” instead of “insufficient”.

• Tables 4 and 5. Minus sign and “to” are both denoted by “-“ when presenting confidence intervals. This is confusing.

• What is new in this study?

• Conclusion. “Younger age was associated with lower scores in all HRQoL subscales”. Where are evidence for that statement?

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Simple, easily understandable, appropriately narrated and explained, and conclusion matched with the objectives and purposes.

It would be informative and useful to narrate in introduction, discussion and conclusion how would this study outcome can be translated into focused tailoring of the treatment plan, bench to bedside. There should be some suggestions for future studies based on the outcome of this study.

Reviewer #2: The study examines the health-related quality of life (HRQoL) in chronic kidney disease (CKD) patients, using the Kidney Disease Quality of Life 36-item (KDQoL-36) questionnaire. The authors employed a cross-sectional design to assess HRQoL in CKD patients attending a hospital in Dhaka, Bangladesh. This design is appropriate for evaluating HRQoL at a single point in time, but as a cross-sectional study, it limits the ability to draw causal conclusions. The use of the KDQoL-36 questionnaire is well-justified, as it is a validated and widely used tool to measure HRQoL in kidney disease patients.The study provides valuable insights into the factors that predict HRQoL in CKD patients in Bangladesh, which could help inform patient care and interventions. However, methodological limitations—including the cross-sectional design, lack of detailed statistical reporting, and the potential for sampling bias—reduce the robustness of the conclusions.Recommend addressing limitations, confounders and clear explanations to further strengthen the article acceptance.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Emran Bin Yunus

Reviewer #2: Yes: Krishna Baradhi

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachments
Attachment
Submitted filename: Recommendations.docx
Revision 1

Manuscript Number: PONE-D-24-41348

Health-related quality of life and its predictors among chronic kidney disease patients: A hospital-based cross-sectional study

PLOS ONE

Dear Editors and Reviewers,

Thank you for your thorough review. Kindly take note that we have highlighted the changes in colors. Below are point to point responses to the Reviewers’ and Editor’s comments.

Response to Reviewer 1

1. Is the manuscript technically sound, and do the data support the conclusions?- Yes

Author response: Thank you very much for your comments.

2. Has the statistical analysis been performed appropriately and rigorously?- Yes

Author response: Noted

3. Have the authors made all data underlying the findings in their manuscript fully available?- Yes

Author response: Noted

4. Is the manuscript presented in an intelligible fashion and written in standard English?- Yes

Author response: Noted

5. Simple, easily understandable, appropriately narrated and explained, and conclusion matched with the objectives and purposes. It would be informative and useful to narrate in introduction, discussion and conclusion how would this study outcome can be translated into focused tailoring of the treatment plan, bench to bedside. There should be some suggestions for future studies based on the outcome of this study.

Author response: Suggestions have been added in the last part of discussion and also in the conclusion part.

Response to Reviewer 2

1. Is the manuscript technically sound, and do the data support the conclusions?- Yes

Author response: Thank you very much for your comments.

2. Has the statistical analysis been performed appropriately and rigorously?- Yes

Author response: Noted

3. Have the authors made all data underlying the findings in their manuscript fully available?- Yes

Author response: Noted

4. Is the manuscript presented in an intelligible fashion and written in standard English?- Yes

Author response: Noted

5. The study examines the health-related quality of life (HRQoL) in chronic kidney disease (CKD) patients, using the Kidney Disease Quality of Life 36-item (KDQoL-36) questionnaire. The authors employed a cross-sectional design to assess HRQoL in CKD patients attending a hospital in Dhaka, Bangladesh. This design is appropriate for evaluating HRQoL at a single point in time, but as a cross-sectional study, it limits the ability to draw causal conclusions. The use of the KDQoL-36 questionnaire is well-justified, as it is a validated and widely used tool to measure HRQoL in kidney disease patients. The study provides valuable insights into the factors that predict HRQoL in CKD patients in Bangladesh, which could help inform patient care and interventions. However, methodological limitations—including the cross-sectional design, lack of detailed statistical reporting, and the potential for sampling bias—reduce the robustness of the conclusions. Recommend addressing limitations, confounders and clear explanations to further strengthen the article acceptance.

Author response: We acknowledge that this study has some limitations, including its cross-sectional design, which prevents causal inferences. Potential confounders like socioeconomic status, cultural factors, and psychological influences may have affected HRQoL scores but were not fully controlled for. Additionally, while the KDQoL-36 is widely used, its relevance in the Bangladeshi context may be limited, and further adaptation or qualitative methods could provide more comprehensive insights. Acknowledging these limitations, future research should focus on longitudinal studies and consider additional factors to better understand HRQoL in CKD patients.

Response to Editor’s comments:

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

Author response: Done Accordingly.

2. Thank you for stating in your Funding Statement:“The project was completed under the research grant scheme for Dhaka University Teacher (2023-24) that is financially supported by the University Grant Commission (UGC), Bangladesh.”Please provide an amended statement that declares *all* the funding or sources of support (whether external or internal to your organization) received during this study, as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now. Please also include the statement “There was no additional external funding received for this study.” in your updated Funding Statement. Please include your amended Funding Statement within your cover letter. We will change the online submission form on your behalf.

Author response: Done Accordingly.

3. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

Author response: Done Accordingly.

4. We note that your Data Availability Statement is currently as follows: [All relevant data are within the manuscript and its Supporting Information files.] Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

Author response: Done Accordingly.

5. Abstract says logistic regression was used in the analysis. But not presented any results from that analysis. Main text says multivariate regression was done, what analyses done here is unclear, please elaborate.

Author response: It will be multiple linear regression and has been corrected in manuscript.

6. Noted the conclusions were generalized to Bangladeshi CKD population. However, the recruitment of participants was from a single hospital. How representative these participants to the Bangladeshi CKD population?

Author response: We recruited study participants from the Kidney Foundation Hospital and Research Institute, Bangladesh, a specialized renal care facility where several renowned nephrologists and consultants provide care. This institution serves patients from various districts across Bangladesh, reflecting the diverse demographics of the country's chronic kidney disease (CKD) population. The incidence of CKD in Bangladesh is estimated at 418,831.07 cases per year. The outpatient services at the hospital accommodate approximately 250 to 300 patients daily, all of whom are Bangladeshi residents. Given this, our study participants can be considered representative of the Bangladeshi CKD population.

This section has been added in the method section.

7. Authors presented a formula used to calculate the sample size, need to define each notation in that formula. Appears the sample size was determined to estimate a proportion with a pre-specified precision. But there is no such an estimation in analysis or results sections. Instead, analysis appeared used linear regression, it is also different to the logistic regression mentioned in the abstract. Therefore sample size estimation incompatible with the analysis done.

Author response: Sample size has been recalculated according to linear regression model.

8. Noted the number of participants was same as the estimated sample size. How did you select that number of people from all eligible patients in that hospital in that period?

Author response: This part has been revised in the method section.

9. Noted the number of participants was same as the estimated sample size. How did you select that number of people from all eligible patients in that hospital in that period?

Author response: This part has been revised in the method section.

10. Main source of the data was questionnaires (in addition extracting from medical records). What is the mode of interviews (online? face to face? assisted? If so by whom? Etc.). Measures taken to mitigate possible bias (eg, social desirability bias) introduced by that?

Author response: It was face to face interview. Trained interviewers collected the data. This part has been improved in the revised manuscript.

11. Main outcome measure is the KDQoL score along with its dimension scores. Could you explain these scores? Eg, what is/are the possible ranges of these scores? Higher scores indicate better or worse HRQoL?

Author response: Detailed information has been added in the revised manuscript. Higher scores indicate the better HRQoL. The Kidney Disease Quality of Life (KDQoL) instrument is a tailored adaptation of HRQoL tools designed for CKD patients. It combines generic HRQoL measures, such as physical and mental health, with CKD-specific domains, including symptoms, disease burden, effects on daily life, patient satisfaction, and work status. Higher KDQoL scores indicate fewer or less severe symptoms, though CKD patients generally score lower than the general population due to the disease's significant impact.

12. Statistical method section says SPSS was used for statistical analysis. Then later says Stata was used for multivariable regression. Does that mean multivariable analysis is not a statistical analysis? Throughout the manuscript authors used the terms multivariate and multivariable interchangeably. These two types of analyses are very different, they haven’t done a multivariate analysis

Author response: It has been corrected in the revised manuscript according to your suggestion.

13. Page 14. Typo. “in sufficient” instead of “insufficient”.

Author response: Done according to your suggestion.

14. Tables 4 and 5. Minus sign and “to” are both denoted by “-“ when presenting confidence intervals. This is confusing.

Author response: It has been corrected according to your suggestion.

15. What is new in this study?

Author response: Thank you for your thoughtful comments. This study makes a unique and innovative contribution by addressing the underexplored area of health-related quality of life (HRQoL) among chronic kidney disease (CKD) patients in Bangladesh, a low-income country with distinct socio-economic and healthcare challenges. Unlike most existing research, which predominantly focuses on high-income settings, this study provides valuable insights from a resource-limited context. By employing the KDQoL™-36 questionnaire and its summary score (KSS), we offer a comprehensive evaluation of physical, mental, and kidney-specific domains of HRQoL. To our knowledge, this is the first study in Bangladesh to apply these tools, enabling a multidimensional understanding of CKD’s impact.

The findings also highlight several novel predictors of HRQoL, such as the influence of employment status, education, marital status, and polypharmacy, alongside clinical factors like CKD stage and comorbidities. These insights provide a foundation for targeted, patient-centered interventions to improve HRQoL in CKD patients. Furthermore, our study addresses critical gaps in global CKD research by contributing context-specific evidence that may inform healthcare policies in similar resource-constrained settings. We believe these factors collectively underscore the significance of our work and its potential to improve CKD care and outcomes.

16. Conclusion. “Younger age was associated with lower scores in all HRQoL subscales”. Where are evidence for that statement?

Author response: The statement was corrected as younger age was associated with higher scores in all HRQoL subscales.

17. While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Author response: Done Accordingly.

Attachments
Attachment
Submitted filename: Response to Reviewer_kdqol.docx
Decision Letter - Ari Samaranayaka, Editor

Health-related quality of life and its predictors among chronic kidney disease patients: A hospital-based cross-sectional study

PONE-D-24-41348R1

Dear Dr. karim,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Ari Samaranayaka, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: I Don't Know

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: Overall, this study makes a valuable contribution to understanding the factors that influence HRQoL among CKD patients, particularly in a Bangladesh-based context. The findings offer important insights into how various socio-demographic, medical, and psychological factors affect patients' quality of life. However, the cross-sectional design and the limited focus on certain psychological and social aspects suggest that further research is needed to deepen our understanding and improve patient care.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: Yes: krishna baradhi

**********

Formally Accepted
Acceptance Letter - Ari Samaranayaka, Editor

PONE-D-24-41348R1

PLOS ONE

Dear Dr. karim,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Ari Samaranayaka

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .